Published in Pharma Investments, Ventures and Law Weekly, April 10th, 2005
For the fourth quarter of 2004, AVI reported a net loss of $5.0 million, or $0.14 per share, compared with a net loss of $3.1 million, or $0.10 per share, for the fourth quarter of 2003. Revenues for the fourth quarter of 2004 were $285,588, compared with $135,181 for the fourth quarter of 2003.
Research and development (R&D) expenses decreased to $3.8 million in the fourth quarter of 2004, compared with $6.4 million in the fourth quarter of 2003. Approximately $2.3 million of this R&D decrease was due to lower contracting costs for the production...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.